Literature DB >> 29531873

The Concomitant Use of Atorvastatin and Amlodipine Leading to Rhabdomyolysis.

Salman Khan1, Imran Khan2, Matthew Novak3, Asish Regmi1, William Difilippo3.   

Abstract

A 65-year-old man, with a history of hypertension and hyperlipidemia, presented with intractable lower back pain, shortness of breath, and decreasing urine output at the emergency room and was admitted after he was found to have elevated creatinine kinase levels of greater than 160,000 U/L. We discontinued all his home medications, which included atorvastatin and amlodipine. We trended his creatine phosphokinase (CPK) level daily and noticed it decreasing significantly off these meds. We hydrated him with normal saline and monitored his kidney functions. By the time he was ready for discharge, his CPK levels were back to normal. This case report summarizes the drug-drug interactions of atorvastatin and amlodipine.

Entities:  

Keywords:  calcium channel blockers; cholesterol; kidney; rhabdomyolysis; statin

Year:  2018        PMID: 29531873      PMCID: PMC5837234          DOI: 10.7759/cureus.2020

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  5 in total

1.  Possible risks to patients receiving statins combined with other medications.

Authors:  Philip D Hansten
Journal:  J Am Coll Cardiol       Date:  2003-02-05       Impact factor: 24.094

2.  Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.

Authors:  A L Mazzu; K C Lasseter; E C Shamblen; V Agarwal; J Lettieri; P Sundaresen
Journal:  Clin Pharmacol Ther       Date:  2000-10       Impact factor: 6.875

Review 3.  Statin myopathy: a review of recent progress.

Authors:  Andrew L Mammen; Anthony A Amato
Journal:  Curr Opin Rheumatol       Date:  2010-11       Impact factor: 5.006

4.  Diagnostic evaluation of rhabdomyolysis.

Authors:  Jessica R Nance; Andrew L Mammen
Journal:  Muscle Nerve       Date:  2015-03-14       Impact factor: 3.217

Review 5.  Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management.

Authors:  Yi-Ting Zhou; Lu-Shan Yu; Su Zeng; Yu-Wen Huang; Hui-Min Xu; Quan Zhou
Journal:  Ther Clin Risk Manag       Date:  2013-12-20       Impact factor: 2.423

  5 in total
  1 in total

1.  Medical Complications of Lung Transplantation.

Authors:  Moo Suk Park
Journal:  J Chest Surg       Date:  2022-08-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.